ORBIMED ADVISORS LLC - 15 Oct 2024 Form 4 Insider Report for Upstream Bio, Inc. (UPB)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
17 Oct 2024, 16:17:52 UTC
Prior SEC filing
10 Oct 2024
Next SEC filing
05 Nov 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC

Key filing fact

ORBIMED ADVISORS LLC filed Form 4 for Upstream Bio, Inc. (UPB) on 17 Oct 2024.

Key facts

  • This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for Upstream Bio, Inc. (UPB).
  • 8 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 17 Oct 2024, 16:17.

Change

  • Previous filing in this sequence was filed on 10 Oct 2024.
  • Current net transaction value: +$14,025,000.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

UPB transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+721,956
Change %
+287%
Price
Shares after
973,716
Date
15 Oct 2024
Ownership
See Footnote
Footnotes
F1, F2, F4
UPB transaction

Common Stock

Purchase

Transaction value
$2,805,000
Shares
+165,000
Change %
+17%
Price
$17.00
Shares after
1,138,716
Date
15 Oct 2024
Ownership
See Footnote
Footnotes
F2, F4
UPB transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+2,887,833
Change %
+287%
Price
Shares after
3,894,873
Date
15 Oct 2024
Ownership
See Footnote
Footnotes
F1, F3, F4
UPB transaction

Common Stock

Purchase

Transaction value
$11,220,000
Shares
+660,000
Change %
+17%
Price
$17.00
Shares after
4,554,873
Date
15 Oct 2024
Ownership
See Footnote
Footnotes
F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

UPB transaction Derivative

Series A redeemable convertible preferred stock

Conversion of derivative security

Transaction value
Shares
-524,500
Change %
-100%
Price
Shares after
0
Date
15 Oct 2024
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
524,500
Exercise price
Footnotes
F1, F2, F4
UPB transaction Derivative

Series A redeemable convertible preferred stock

Conversion of derivative security

Transaction value
Shares
-2,098,000
Change %
-100%
Price
Shares after
0
Date
15 Oct 2024
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
2,098,000
Exercise price
Footnotes
F1, F3, F4
UPB transaction Derivative

Series B redeemable convertible preferred stock

Conversion of derivative security

Transaction value
Shares
-197,456
Change %
-100%
Price
Shares after
0
Date
15 Oct 2024
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
197,456
Exercise price
Footnotes
F1, F2, F4
UPB transaction Derivative

Series B redeemable convertible preferred stock

Conversion of derivative security

Transaction value
Shares
-789,833
Change %
-100%
Price
Shares after
0
Date
15 Oct 2024
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
789,833
Exercise price
Footnotes
F1, F3, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

Footnote F2

These securities are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("Israel GP") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited ("Advisors II") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors II may be deemed to have voting and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. Advisors II exercises voting and investment power through an investment committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits ("Chimovits"), each of whom disclaims beneficial ownership of the securities held by OIP II.

Footnote F3

These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII.

Footnote F4

Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .